Stoke Therapeutics(STOK.US) Officer Sells US$137.46K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Ticho Barry sold 10,000 shares of common stock on Jul 1, 2024 at an average price of $13.7458 for a total value of $137.46K.Source: Announcement What is statement
Stoke Therapeutics(STOK.US) Officer Sells US$32,778.87 in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Nash Huw M. sold 2,500 shares of common stock on Jul 2, 2024 at an average price of $13.112 for a total value of $32,778.87.Source: Announcement What is statement
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
Needham analyst Joseph Stringer maintains $Stoke Therapeutics(STOK.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 39.9% and
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
Stoke Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 65.29% Needham $22 → $22 Reiterates Buy → Buy 05/07/2024 162.96% HC Wainwright & Co. $35 → $35
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Enerpac Tool Group Corp. (NYSE:EPAC) to
Stoke Therapeutics Announces Chief Operating Officer Huw Nash To Step Down, Will Continue As Chief Business Officer Effective June 18, 2024
Stoke Therapeutics Announces Chief Operating Officer Huw Nash To Step Down, Will Continue As Chief Business Officer Effective June 18, 2024
Express News | Stoke Therapeutics Inc Files for Shelf of up to 10.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
Stoke Therapeutics(STOK.US) Officer Sells US$152.19K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Ticho Barry sold 10,000 shares of common stock on Jun 3, 2024 at an average price of $15.2185 for a total value of $152.19K.Source: Announcement What is statement
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
Stoke Therapeutics(STOK.US) Officer Sells US$769.5K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Nash Huw M. sold 50,000 shares of common stock on May 20, 2024 at an average price of $15.39 for a total value of $769.5K.Source: Announcement What is statement o
Stoke Therapeutics(STOK.US) Officer Sells US$653.53K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Kaye Edward M. MD sold 42,350 shares of common stock on May 20, 2024 at an average price of $15.4316 for a total value of $653.53K.Source: Announcement What is st
Stoke Therapeutics(STOK.US) Officer Sells US$129.33K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Allan Jonathan sold 8,599 shares of common stock on May 20, 2024 at an average price of $15.0398 for a total value of $129.33K.Source: Announcement What is statem
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing
Edward M. Kaye, Director, CEO, on May 20, 2024, sold 42,350 shares in Stoke Therapeutics (STOK) for $653,529. Following the Form 4 filing with the SEC, Kaye has control over a total of 27,000 shares o
Form 144 | Stoke Therapeutics(STOK.US) Officer Proposes to Sell 119.53K in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $Stoke Therapeutics(STOK.US)$ Officer JONATHAN ALLAN intends to sell 8,599 shares of its common stock on May 20, with a total market value of approximately $119.53K.
Form 144 | Stoke Therapeutics(STOK.US) Officer Proposes to Sell 695K in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $Stoke Therapeutics(STOK.US)$ Officer HUW MICHAEL NASH intends to sell 50,000 shares of its common stock on May 20, with a total market value of approximately $695K.
Form 144 | Stoke Therapeutics(STOK.US) Director Proposes to Sell 588.67K in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $Stoke Therapeutics(STOK.US)$ Director EDWARD M KAYE intends to sell 42,350 shares of its common stock on May 20, with a total market value of approximately $588.67K.